Our findings demonstrate that TrkA protein expression is increased in HER2-positive breast cancers, which suggests TrkA as a complementary therapeutic target for these tumours, particularly those which are resistant to anti-HER2 therapies. This evidence concerns the gene NTRK1 and breast carcinoma.